LP
IRLA

LMR Partners’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

LMR Partners’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-143
Closed -$360K – 1333
2021
Q4 		$360K Buy
+143
New +$873K ﹤0.01% 988

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LMR Partners's IRLA Position: Q1 2022 in Review

LMR Partners sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2022, closing a stake of 143 shares — an estimated $360K sold.

LMR Partners first reported a position in IRLA in Q4 2021 and held it in 1 quarter. The position peaked at $360K in Q4 2021. 85 funds tracked by Wall St. Rank hold IRLA as of Q1 2022.

  • LMR Partners reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • LMR Partners sold 143 IRulya Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $360K.
  • LMR Partners first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • LMR Partners's IRulya Therapeutics Inc. Common Stock position peaked at $360K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2022.

Based on LMR Partners's 13F filing for Q1 2022, filed 16 May 2022.